KunWha Pharmaceutical Co., Ltd.
Quick facts
Phase 3 pipeline
- KW21052 · Diabetes
KW21052 is a small molecule that targets the SGLT2 receptor. - Lyrica (low dose) · Neurology; Pain Management
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. - Placebo of KW21052
This is a placebo control and contains no active pharmaceutical ingredient. - Placebo of Lyrica
This is a placebo control formulation used in clinical trials to compare against the active drug Lyrica (pregabalin).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: